Josh Haimson

Josh Haimson is the co-founder and CEO of Inductive Bio, a New York based AI company building software to speed up small molecule drug discovery. Before starting Inductive in 2024 with Ben Birnbaum, Josh ran product for the machine learning and data curation teams at Flatiron Health, generating real-world evidence across a network of more than 2 million cancer patients. The company raised a $25M Series A in May 2025 led by Obvious Ventures, and its Compass platform helps chemists predict a molecule's ADMET properties before it is ever synthesized, attacking the 'whack-a-mole' bottleneck that slows drug development.